CTRI/2024/03/064383进行中（未招募）未知
An open label, multi-center, randomized, two-treatment, two period, two-sequence, two-way cross-over, single dose, Bioequivalence (BE) study with pharmacokinetic (PK) endpoints of Paclitaxel 100mg/vial injectable suspension at a dose of 260 mg/m2 of Anbison Lab, China with ABRAXANE® 100mg/vial for Injectable suspension at a dose of 260 mg/m2 of Celgene Corporation Summit, NJ 07901 in subject with metastatic Breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. - NI
Anbison Lab. Co., Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Willing and able to provide written informed consent prior to any study-related activities being performed and to follow protocol requirements
- •2. Female subjects aged 18 to 65 years (both inclusive) and having Body Mass Index at least 17 kg per m2.
- •3. Subjects with histopathologically or cytologically confirmed breast cancer
- •4. Subjects with breast cancer after failure of combination chemotherapy for metastatic disease or having relapse within 6 months of adjuvant chemotherapy. (Prior therapy should have included an anthracycline unless clinically contraindicated).
- •5. Life expectancy of greater than 90 days at the time of enrolment.
- •6. Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to2
- •7. Acceptable hematology status
- •a. Hemoglobin greater than or equal to 9 g per dL
- •b. Absolute neutrophil count (ANC) greater than or equal to 1500 cells per micro L
- •c. Platelet count greater than or equal to 1, 00,000 cells per mm3
- •8. Acceptable liver function:
- •a. Alanine aminotransferase (ALT) less than or equal to2.5 X upper limit of normal (ULN)
- •b. Aspartate aminotransferase (AST) less than or equal to2.5 X ULN
- •c. Bilirubin less than or equal to1.5 X ULN
- •d. Alkaline phosphatase less than or equal to2.5 X ULN
- •9. Subjects with Creatinine clearance greater than or equal to 45 mL per minute
- •10. Subjects of child-bearing potential with negative serum pregnancy test at screening and negative urine pregnancy test at Day 0.
- •11. Women of child bearing potential, (defined as women physiologically capable of becoming pregnant, unless they are using effective method of contraception during treatment with the investigational product) practicing two acceptable methods of contraception during the study and at least 6 months after the last dose of study medication. Female subjects of non-child bearing potential or who have completed menopause are not required to use effective method of contraception during the study.
- •Acceptable methods of contraception are:
- •a. Hormonal method (including oral, vaginal ring, transdermal patch, implanted or injection) started at least 7 days prior to Day 0 plus one barrier method (cervical cap, diaphragm, contraceptive sponge, vaginal spermicide, female or male condom)
- •b. Intrauterine device (IUD) or intrauterine system placed at least 7 days prior to Day 0.
- •c. Two barrier method used together (cervical cap, diaphragm, contraceptive sponge, vaginal spermicide, male or female condom)
- •d. Male sterilization (at least 6 months prior to the screening, should be the sole male partner for that subject) plus one additional contraception method (hormonal or barrier method)
- •e. Documented tubal sterilization (tubal ligation or trans cervical tubal occlusion with documentation of occlusion 6 months post-procedure)
- •f. Total abstinence; partial abstinence is not acceptable (no sex or genital contact with a male partner)
- •12. No history of addiction to any recreational drug or drug dependence or alcohol addiction within past one year.
- •13. Subject should have recovered from the toxicity or adverse effects of previous radiation, surgery and/or chemotherapy as per investigators assessment before administration of study intervention.
排除标准
- •1. Known hypersensitivity to Paclitaxel, other taxane products or the components of Paclitaxel protein-bound particles for injectable suspension (albumin-bound) or to any of the excipients.
- •2. Subjects with history of other malignancy in the past.
- •3. History or presence of sepsis or pneumonitis.
- •4. Subjects with = Grade 2 peripheral neuropathy.
- •5. Presence of any uncontrolled systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.).
- •6. Subjects with known history or current symptoms of unstable angina or myocardial infarction within the past 6 months prior to screening visit.
- •7. Subjects with electrocardiographic evidence of acute ischemic or active conduction system abnormalities at screening assessment.
- •8. Subjects taking any of the inhibitors or inducers of either CYP2C8 or CYP3A4.
- •9. Known CNS metastasis.
- •10. Subjects with current clinical or laboratory evidence of active infection
- •11. Subjects with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).
- •12. Major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product.
- •13. Surgical or other non-healing wounds.
- •14. Participation in any clinical study within 90 days before the first dose of Investigational Product.
- •15. Loss of =350 ml (1 unit) of blood within 90 days before the first dose of Investigational Product.
- •16. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements.
- •17. Has not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable) and fatigue (Grade 2 is acceptable) (Per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], V 5.0).
- •18. Pregnant or lactating women.
研究者
相似试验
尚未招募
不适用
Bioequivalence study of doxorubicin hydrochloride liposome injection 2mg/mL in ovarian cancer subjects under fasting conditions.CTRI/2020/05/025245Shanghai Jingfeng Pharmaceuticals Group Co Ltd China
招募中
不适用
Bioequivalence Study of Leuprolide Depot Injection 7.5 mg of with LUPRON Depot (leuprolide acetate for depot suspension) 7.5 mg in subjects with locally advanced and/or metastatic prostate cancer undergoing initial therapy.CTRI/2022/04/041602American Regent Inc
招募中
1 期
Bioavailability study between Bortezomib for Injection 3.5 mg/0.2 mL and VELCADE 3.5 mg powder for solution for injection at a dose of 1.3 mg/m2CTRI/2020/06/025971Shilpa Medicare Limited
已完成
不适用
Bioavailability study of Bortezomib for Injection 3.5 mg/vial in patients with Multiple MyelomaCTRI/2019/03/018107Shilpa Medicare Limited6
已完成
不适用
A comparative study of Doxorubicin Hydrochloride in ovarian and/or breast cancer patients.CTRI/2017/07/009118Dr Reddys Laboratories Ltd85